gsk consumer (Emkay) Weak volumes impact performance

Lower volume growth hampers performance.; Witnessed 5% input cost inflation. EBITDA maintained at 20.5%; New launches performing well; Q2 volume growth remains a key catalyst. Maintain ACCUMULATE
Date Rating Target Price Recommendation Price Broker house
2 May 2011 accumulate 2590 2383 Emkay Report

No comments:

Post a Comment